Overview
Multicystic dysplastic kidney (MCDK), also known as multicystic renal dysplasia, is a congenital condition in which one or both kidneys fail to develop normally during fetal life, resulting in a non-functioning kidney replaced by multiple cysts of varying sizes separated by dysplastic tissue. It is one of the most common causes of an abdominal mass in newborns. The condition is thought to arise from abnormal interaction between the ureteric bud and the metanephric mesenchyme during embryonic kidney development, often associated with ureteral atresia. MCDK most commonly affects only one kidney (unilateral), with the contralateral kidney typically undergoing compensatory hypertrophy to maintain normal renal function. The affected kidney lacks normal renal architecture and is essentially non-functional. In unilateral cases, most children are asymptomatic and are diagnosed prenatally through routine ultrasound screening, which reveals a kidney replaced by multiple non-communicating cysts. The affected kidney usually involutes (shrinks) over time, and many cases resolve spontaneously during childhood. However, the contralateral kidney may have associated abnormalities such as vesicoureteral reflux or ureteropelvic junction obstruction in a proportion of cases, which requires monitoring. Bilateral MCDK is incompatible with life due to the absence of functional renal tissue, leading to oligohydramnios and pulmonary hypoplasia. Management of unilateral MCDK is generally conservative, involving serial ultrasound monitoring to track involution of the affected kidney and to ensure the health and compensatory growth of the contralateral kidney. Nephrectomy (surgical removal of the affected kidney) was historically performed routinely but is now typically reserved for cases with complications such as persistent enlargement, hypertension, recurrent infections, or concern for malignancy, though the risk of malignant transformation (such as Wilms tumor) is considered extremely low. Long-term follow-up includes monitoring blood pressure and renal function, as some patients may develop hypertension or mild renal impairment over time.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Multicystic dysplastic kidney.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Multicystic dysplastic kidney at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Multicystic dysplastic kidney.
Community
No community posts yet. Be the first to share your experience with Multicystic dysplastic kidney.
Start the conversation →Latest news about Multicystic dysplastic kidney
No recent news articles for Multicystic dysplastic kidney.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Multicystic dysplastic kidney
What is Multicystic dysplastic kidney?
Multicystic dysplastic kidney (MCDK), also known as multicystic renal dysplasia, is a congenital condition in which one or both kidneys fail to develop normally during fetal life, resulting in a non-functioning kidney replaced by multiple cysts of varying sizes separated by dysplastic tissue. It is one of the most common causes of an abdominal mass in newborns. The condition is thought to arise from abnormal interaction between the ureteric bud and the metanephric mesenchyme during embryonic kidney development, often associated with ureteral atresia. MCDK most commonly affects only one kidney
How is Multicystic dysplastic kidney inherited?
Multicystic dysplastic kidney follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Multicystic dysplastic kidney typically begin?
Typical onset of Multicystic dysplastic kidney is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Multicystic dysplastic kidney?
11 specialists and care centers treating Multicystic dysplastic kidney are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.